Abstract: The present invention provides a biocompatible material, such as a guided tissue regeneration membrane (GTR membrane), a guided bone regeneration membrane (GBR membrane), a sheet material, a patch material, or a compensation material, which has a porous structure to allow transportation of the various factors to induce or facilitate the regeneration. The present invention also provides a manufacturing method for the biocompatible material. The present invention forms a biocompatible material from a nano- or microfiber nonwoven fabric fabricated by an electrospinning method, thereby easily producing a porous biocompatible material that allows transportation of the various factors to induce or facilitate the regeneration.

Abstract: The present invention provides a biocompatible membrane which has a configuration that conforms well to an affected part and can be used in fields such as dentistry, oral surgery, orthopedics, etc., by a compatible membrane production process in which a biocompatible material is subjected to a lamination forming process or a powder electrostatic coating process. Examples of lamination forming processes include (a) selective laser sintering, (b) powder adherence, (c) fused deposition molding, (d) laminated object manufacturing, and (e) optical molding. The biocompatible membrane is useful as, for example, a tissue regeneration membrane or a bone regeneration membrane for periodontal tissue, bone tissue, and like tissue regeneration treatment.

Abstract: A pharmaceutical or veterinary composition for activating the function of phygocytes comprising as an effective ingredient a certain tocopheryl glycoside. The composition is useful for treating infectious diseases and malignant tumor.

Abstract: A pharmaceutical composition for treating viral diseases, such as pasta, gargle, gel, ointment, suppository, spray, etc., containing interferon in a stable state which comprises an effective amount of human interferon, 15 to 60% by weight of a tri or higher polyhydric sugar alcohol and an organic acid buffer as stabilizers, and a conventional pharmaceutical carrier or diluent. The pH of the composition is about 3 to 6. Optionally, the composition can further contain as a stabilizer an anionic surfactant and/or albumin.

Abstract: A pharmaceutical composition for treating erythematodes, particularly, lupus erythematodes discoides, or mycosis, particularly, candidasis, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from erythematodes and mycosis by using this composition is also provided.

Abstract: A pharmaceutical composition for treating keratosic disorders of skin and mucosa, particularly, lichen planus and leukoplakia, by topical or local administration which comprises an effective amount of human interferon, a trihydric or more higher polyhydric sugar alcohol, an organic acid buffer and, optionally, an anionic surfactant and albumin, and a conventional pharmaceutical carrier or diluent. A method for treating a human subject suffering from keratosic disorders of skin and mucosa by using this composition is also provided.